Abstract | OBJECTIVE: METHODS: A single institution, retrospective review from 1995 to 2012 of patients receiving oxaliplatin for treatment of recurrent or progressive EOC, PPC, or FTC was performed. Data collected included patient demographics, diagnosis date, prior chemotherapy regimens, platinum-free interval(s), prior hypersensitivity reactions, oxaliplatin toxicity, length of therapy, disease response, and last follow-up. Those who received ≥1 cycles were included. A response to therapy was determined after ≥2 cycles. RESULTS: CONCLUSIONS:
|
Authors | Sarah E Taylor, Tiffany L Beck, Thomas C Krivak, Kristin K Zorn, Joseph L Kelley, Robert P Edwards |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 134
Issue 1
Pg. 68-72
(Jul 2014)
ISSN: 1095-6859 [Electronic] United States |
PMID | 24769036
(Publication Type: Journal Article)
|
Copyright | Copyright © 2014 Elsevier Inc. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- DNA Adducts
- Organoplatinum Compounds
- Oxaliplatin
- Carboplatin
- Cisplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carboplatin
(adverse effects)
- Carcinoma, Ovarian Epithelial
- Cisplatin
(administration & dosage)
- DNA Adducts
(metabolism)
- Drug Hypersensitivity
(etiology)
- Fallopian Tube Neoplasms
(drug therapy)
- Female
- Humans
- Middle Aged
- Neoplasms, Glandular and Epithelial
(drug therapy)
- Organoplatinum Compounds
(administration & dosage, adverse effects, therapeutic use)
- Ovarian Neoplasms
(drug therapy)
- Oxaliplatin
- Retrospective Studies
- Salvage Therapy
|